Human leukocyte antigen class II antibodies and transplant outcome

Transplantation

Volumn 86, Issue 5, 2008, Pages 638-640

  Duquesnoy, Rene J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GENE PRODUCT; HLA A2 ANTIGEN; HLA ANTIBODY; HLA DR ANTIGEN; ALLOANTIBODY; HLA ANTIGEN CLASS 2;

ACUTE GRAFT REJECTION; ANTIGEN SPECIFICITY; B LYMPHOCYTE; CHRONIC GRAFT REJECTION; GLOMERULOPATHY; GRAFT FAILURE; GRAFT SURVIVAL; HLA SYSTEM; HUMAN; KIDNEY TRANSPLANTATION; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; T LYMPHOCYTE; TRANSPLANTATION; TREATMENT OUTCOME; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOLOGY; PROTEIN CONFORMATION;

GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR ANTIGENS; HUMANS; ISOANTIBODIES; MODELS, MOLECULAR; PROTEIN CONFORMATION; RISK FACTORS; TRANSPLANTATION IMMUNOLOGY;

EID: 53449087941     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318183749a     Document Type: Note

References (24)

1. Takemoto S, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033.
2. Schoenemann C, Groth J, Leverenz S, et al. HLA class I and class II antibodies: Monitoring before and after kidney transplantation. Transplantation 1998; 65: 1519.
3. Scornik JC, Zander DS, Baz MA, et al. Susceptibility of lung transplants to preformed donor-specific HLA antibodies as detected by flow cy-tometry. Transplantation 1999; 68: 1542.
4. Iniotaki-Theodoraki AG, Boletis JN, Trigas G, et al. Humoral immune reactivity against human leukocyte antigen (HLA)-DQ graft molecules in the early posttransplantation period. Transplantation 2003; 75: 1601.
5. Itescu S, Tung TC, Burke EM, et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 1998; 98: 786.
6. Pollinger HS, Stegall MD, Gloor JM, et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 2007; 7: 857.
7. Vasilescu ER, Ho EK, de la Torre L, et al. HLA antibodies in heart transplantation. Transplant Immunol 2004; 12: 177.
8. Muller-Steinhardt M, Fricke L, Kirchner H, et al. Monitoring of anti-HLA class I and II antibodies by flow cytometry in patients after first cadaveric kidney transplantation. Clin Transplant 2000; 14: 85.
9. Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
10. Reinsmoen N, Nelson K, Zeevi A. Anti-HLA antibody analysis and crossmatching in heart and lung transplantation. Transplant Immunol 2004; 13: 63.
11. Qiu J, Cai J, Terasaki PI, et al. Detection of antibodies to HLA-DP in renal transplant recipients using single antigen beads. Transplantation 2005; 80: 1511.
12. Cai J, Terasaki P, Mao Q, et al. Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens. Am J Transplant 2006; 6: 2947.
13. Langan LL, Park LP, Hughes TL, et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007; 7: 847.
14. Campos E, Tedesco-Silva H, Machado P, et al. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2007; 6: 2316.
15. Issa N, Cosio F, Gloor J, et al. Tranplant glomerulopathy: Risk and prognosis related to anti-HLA class II antibody levels. Transplantation (in press).
16. Mahoney RJ, Taranto S, Edwards E. B-cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients. HumImmunol 2002; 63: 324.
17. Gebel H, Bray R, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs risk. Am J Transplant 2003; 3: 1488.
18. Duquesnoy R. A structurally based approach to determine HLA. Compatibility at the humoral immune level. Hum Immunol 2006; 67: 847.
19. Duquesnoy RJ, Askar M. HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ and HLA-DP. Hum Immunol 2007; 68: 12.
20. Duquesnoy R, Awadalla Y, Lomago J, et al. Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR, DQ, DP epitopes. Transplant Immunol 2008; 18: 352.
21. Dankers MKA, Witvliet MD, Roelen DL, et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched HLA antigens. Transplantation 2004; I28: 1236.
22. Goodman R, Taylor C, O'Rourke C, et al. Utility of HLAMatchmaker and single-antigen HLA-antibody detection beads for identification of acceptable mismatches in highly sensitised patients awaiting kidney transplantation. Transplantation 2006; 81: 1331.
23. Mihaylova A, Baltadjieva D, Boneva P, et al. Clinical relevance of anti-HLA antibodies detected by flow-cytometry bead-based assays - Single-center experience. Hum Immunol 2006; 67: 787.
24. Kosmoliaptsis V, Bradley A, Sharples L, et al. Predicting the immuno-genicity of HLA class I alloantigens using structural epitope analysis determined by HLAMatchmaker. Transplantation 2008; 85: 1817.